These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31967663)

  • 1. Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia.
    Zou Y; Yang S; Wang S; Lv B; Xiu L; Li L; Lee SW; Chin CT; Pocock SJ; Huo Y; Yu B
    Clin Cardiol; 2020 Apr; 43(4):346-354. PubMed ID: 31967663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study.
    Zheng B; Huo Y; Lee SW; Sawhney JPS; Kim HS; Krittayaphong R; Pocock SJ; Nhan VT; Alonso Garcia A; Chin CT; Jiang J; Jan S; Vega AM; Hayashi N; Ong TK
    Clin Cardiol; 2020 Sep; 43(9):999-1008. PubMed ID: 32618009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term follow-up of antithrombotic management patterns in patients hospitalized with acute coronary syndrome: Indian subgroup of EPICOR Asia study.
    Sawhney JPS; Mullasari A; Kahali D; Mehta V; Nair T; Kaul U; Hirematth MS
    Indian Heart J; 2019; 71(1):25-31. PubMed ID: 31000179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study.
    Stepinska J; Wojtkowska I; Annemans L; Danchin N; Pocock SJ; de Werf FV; Medina J; Bueno H
    Curr Vasc Pharmacol; 2020; 18(1):92-99. PubMed ID: 30588886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study.
    Zhou J; Chin CT; Huang X; Guo N; Wu Y; Yu B; Qiao S; Chen J; Han Y; Ge J; Pocock SJ; Huo Y; Wang Z; Yuan Z
    Int J Cardiol; 2021 Mar; 327():19-24. PubMed ID: 33186669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.
    Bardají A; Leal M; Arrarte V; Garcia-Moll X; Pérez de Isla L; Bueno H
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27885830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia).
    Huo Y; Lee SW; Sawhney JP; Kim HS; Krittayaphong R; Nhan VT; Alonso-Garcia A; Han YL; Ge J; Chin CT; Ong TK; Jan S; Itoh Y; Vega AM; Pocock S
    Clin Cardiol; 2015 Sep; 38(9):511-9. PubMed ID: 26206158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia.
    Zhang S; Wang W; Sawhney JPS; Krittayaphong R; Kim HS; Nhan VT; Lee SW; Ong TK; Chin CT; Pocock SJ; Huo Y; Qian J; Ge J
    Int J Cardiol; 2020 Jul; 310():16-22. PubMed ID: 32192746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
    Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current patterns of antithrombotic and revascularisation therapy in patients hospitalised for acute coronary syndromes. Data from the Polish subset of the EPICOR study.
    Wojtkowska I; Stępińska J; Stępień-Wojno M; Sobota M; Kopaczewski J; Reszka Z; Kurzelewski M; Medina J
    Kardiol Pol; 2017; 75(5):445-452. PubMed ID: 28281731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy.
    Danchin N; Puymirat E; Cayla G; Cottin Y; Coste P; Gilard M; Goldstein P; Braun F; Belle L; Montalescot G; Ferrières J; Schiele F; Simon T;
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e007241. PubMed ID: 30354592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction.
    Campodonico J; Cosentino N; Milazzo V; Rubino M; De Metrio M; Marana I; Moltrasio M; Grazi M; Lauri G; Bonomi A; Veglia F; Chiorino E; Assanelli E; Bartorelli AL; Marenzi G
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):407-413. PubMed ID: 29669424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial Infarction.
    Kim J; Song YB; Oh JH; Cho DK; Lee JB; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC; Doh JH; Hahn JY;
    Circ J; 2021 May; 85(6):817-825. PubMed ID: 33431720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study.
    Huo Y; Lee SW; Sawhney JPS; Kim HS; Krittayaphong R; Pocock SJ; Nhan VT; Alonso-Garcia Á; Chin CT; Jiang J; Jan S; Vega AM; Hayashi N; Ong TK
    Int J Cardiol; 2020 Sep; 315():1-8. PubMed ID: 32389764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score.
    Bian L; Qiu M; Li Y; Xu X; Li J; Ma S; Qi Z; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():665-673. PubMed ID: 31957965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Carrero JJ; Varenhorst C; Jensevik K; Szummer K; Lagerqvist B; Evans M; Spaak J; Held C; James S; Jernberg T
    Kidney Int; 2017 Jan; 91(1):216-226. PubMed ID: 27865441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.